Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 119, Issue 5, Pages 564-582Publisher
WILEY
DOI: 10.1002/jso.25421
Keywords
biomarkers; chemotherapy; colorectal cancer; immunotherapy; targeted therapy
Ask authors/readers for more resources
The treatment of metastatic colorectal cancer has evolved over the last two decades with the FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review the impact of sidedness, RAS, BRAF, HER-2, and other immune biomarkers on metastatic colorectal cancer treatment selection and sequencing in both the palliative and curative intent settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
